技術簡介
新型微脂體多孔微粒包覆活性藥物具深層肺部傳輸效果,並可延長藥物於肺部之曝藥時間。
Abstract
New liposome-embedding porous microparticles for deep lung delivery of active ingredient and prolonging the drug retention time in the lung tissue
技術規格
pirfenidone 微脂體多孔微粒平均粒徑ca. 4~5um,tapped density介於0.16~0.4 g/mL,並具備體外藥物緩釋效果,空氣動力質量中位直徑 3.260mm,細微粒子比率(<5mm, %)=50.44%,此外經由氣管內給藥大鼠肺部之pirfenidone其t1/2為傳統配方之2.8倍。
Technical Specification
The developed pirfenidone-liposome porous particles had particle size of 4~5μm, low density (0.16~0.4 g/mL) and in vitro sustained-release behavior. The aerodynamic evaluation of pirfenidone-liposome porous particles showed that the mass median aerodynamic diameter (MMAD) was 3.26μm and fine particle fraction (FPF) reached up to 50.44%. Most importantly, pirfenidone-liposome porous particles provided a longer half-life (t1/2b; 2.8-fold) when compared with the pirfenidone lactose formulation in a rat pharmacokinetic study via intratracheal instillation.
技術特色
新型微脂體多孔微粒包覆活性藥物具深層肺部傳輸效果,並可延長藥物於肺部之曝藥時間。
應用範圍
肺部藥物遞送
接受技術者具備基礎建議(設備)
生物、化學實驗室
接受技術者具備基礎建議(專業)
生技製藥
聯絡資訊
聯絡人:鄭淑珍 標靶藥物與傳輸技術組
電話:+886-3-5743973 或 Email:itriA00563@itri.org.tw
客服專線:+886-800-45-8899
傳真:+886-3-5918388